25 XP   0   0   10

Immunovant Inc
Buy, Hold or Sell?

Let's analyse Immunovant together

PenkeI guess you are interested in Immunovant Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Immunovant Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Immunovant Inc

I send you an email if I find something interesting about Immunovant Inc.

Quick analysis of Immunovant (30 sec.)










What can you expect buying and holding a share of Immunovant? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.68
Expected worth in 1 year
$6.50
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$1.82
Return On Investment
6.4%

For what price can you sell your share?

Current Price per Share
$28.32
Expected price per share
$19.50 - $39.55
How sure are you?
50%

1. Valuation of Immunovant (5 min.)




Live pricePrice per Share (EOD)

$28.32

Intrinsic Value Per Share

$-15.96 - $-18.76

Total Value Per Share

$-11.29 - $-14.08

2. Growth of Immunovant (5 min.)




Is Immunovant growing?

Current yearPrevious yearGrowGrow %
How rich?$679.3m$429.1m-$30.8m-7.7%

How much money is Immunovant making?

Current yearPrevious yearGrowGrow %
Making money-$60.8m-$49.6m-$11.1m-18.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Immunovant (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#79 / 1016

Most Revenue
#812 / 1016

Most Profit
#918 / 1016

Most Efficient
#182 / 1016

What can you expect buying and holding a share of Immunovant? (5 min.)

Welcome investor! Immunovant's management wants to use your money to grow the business. In return you get a share of Immunovant.

What can you expect buying and holding a share of Immunovant?

First you should know what it really means to hold a share of Immunovant. And how you can make/lose money.

Speculation

The Price per Share of Immunovant is $28.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Immunovant.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Immunovant, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.68. Based on the TTM, the Book Value Change Per Share is $0.46 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Immunovant.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.35-1.2%-0.42-1.5%-0.34-1.2%-0.25-0.9%-0.25-0.9%
Usd Book Value Change Per Share2.9410.4%0.461.6%-0.16-0.5%0.230.8%0.230.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.9410.4%0.461.6%-0.16-0.5%0.230.8%0.230.8%
Usd Price Per Share42.13-28.75-8.19-17.43-17.43-
Price to Earnings Ratio-29.76--18.08--5.54--20.62--20.62-
Price-to-Total Gains Ratio14.32--47.24-19.17-500.80-500.80-
Price to Book Ratio9.01-11.64-2.82-9.20-9.20-
Price-to-Total Gains Ratio14.32--47.24-19.17-500.80-500.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share28.32
Number of shares35
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.460.23
Usd Total Gains Per Share0.460.23
Gains per Quarter (35 shares)15.948.18
Gains per Year (35 shares)63.7632.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10645403323
2012811806556
3019118209889
402552460131122
503193100164155
603833740196188
704464380229221
805105020262254
905745660295287
1006386300327320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.020.00.00.0%0.020.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%8.012.00.040.0%8.012.00.040.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.020.00.0%0.00.020.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%8.012.00.040.0%8.012.00.040.0%

Fundamentals of Immunovant

About Immunovant Inc

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Fundamental data was last updated by Penke on 2024-04-11 11:45:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Immunovant Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Immunovant earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Immunovant to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Immunovant Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Immunovant is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Immunovant to the Biotechnology industry mean.
  • -7.2% Return on Assets means that Immunovant generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Immunovant Inc:

  • The MRQ is -7.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.2%TTM-15.8%+8.5%
TTM-15.8%YOY-10.8%-5.0%
TTM-15.8%5Y-9.2%-6.6%
5Y-9.2%10Y-9.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.2%-13.6%+6.4%
TTM-15.8%-12.9%-2.9%
YOY-10.8%-11.9%+1.1%
5Y-9.2%-14.2%+5.0%
10Y-9.2%-16.2%+7.0%
1.1.3. Return on Equity

Shows how efficient Immunovant is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Immunovant to the Biotechnology industry mean.
  • -7.6% Return on Equity means Immunovant generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Immunovant Inc:

  • The MRQ is -7.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.6%TTM-18.0%+10.4%
TTM-18.0%YOY-11.7%-6.3%
TTM-18.0%5Y-10.3%-7.7%
5Y-10.3%10Y-10.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.6%-17.0%+9.4%
TTM-18.0%-16.1%-1.9%
YOY-11.7%-15.4%+3.7%
5Y-10.3%-20.0%+9.7%
10Y-10.3%-21.1%+10.8%

1.2. Operating Efficiency of Immunovant Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Immunovant is operating .

  • Measures how much profit Immunovant makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Immunovant to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Immunovant Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y--624.7%+624.7%
1.2.2. Operating Ratio

Measures how efficient Immunovant is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Immunovant Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y-7.857-7.857

1.3. Liquidity of Immunovant Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Immunovant is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 22.14 means the company has $22.14 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Immunovant Inc:

  • The MRQ is 22.141. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.382. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ22.141TTM11.382+10.759
TTM11.382YOY14.355-2.973
TTM11.3825Y14.912-3.530
5Y14.91210Y14.9120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.1413.930+18.211
TTM11.3824.251+7.131
YOY14.3555.436+8.919
5Y14.9126.045+8.867
10Y14.9126.363+8.549
1.3.2. Quick Ratio

Measures if Immunovant is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Immunovant to the Biotechnology industry mean.
  • A Quick Ratio of 21.56 means the company can pay off $21.56 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Immunovant Inc:

  • The MRQ is 21.555. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.863. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.555TTM10.863+10.692
TTM10.863YOY13.875-3.011
TTM10.8635Y97.051-86.187
5Y97.05110Y97.0510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.5553.629+17.926
TTM10.8634.065+6.798
YOY13.8755.397+8.478
5Y97.0515.993+91.058
10Y97.0516.277+90.774

1.4. Solvency of Immunovant Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Immunovant assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Immunovant to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.05 means that Immunovant assets are financed with 4.5% credit (debt) and the remaining percentage (100% - 4.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Immunovant Inc:

  • The MRQ is 0.045. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.109. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.045TTM0.109-0.064
TTM0.109YOY0.076+0.033
TTM0.1095Y0.119-0.010
5Y0.11910Y0.1190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0450.332-0.287
TTM0.1090.334-0.225
YOY0.0760.268-0.192
5Y0.1190.366-0.247
10Y0.1190.390-0.271
1.4.2. Debt to Equity Ratio

Measures if Immunovant is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Immunovant to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.7% means that company has $0.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Immunovant Inc:

  • The MRQ is 0.047. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.124. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.047TTM0.124-0.077
TTM0.124YOY0.083+0.042
TTM0.1245Y0.704-0.579
5Y0.70410Y0.7040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0470.381-0.334
TTM0.1240.390-0.266
YOY0.0830.334-0.251
5Y0.7040.434+0.270
10Y0.7040.466+0.238

2. Market Valuation of Immunovant Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Immunovant generates.

  • Above 15 is considered overpriced but always compare Immunovant to the Biotechnology industry mean.
  • A PE ratio of -29.76 means the investor is paying $-29.76 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Immunovant Inc:

  • The EOD is -20.006. Based on the earnings, the company is expensive. -2
  • The MRQ is -29.762. Based on the earnings, the company is expensive. -2
  • The TTM is -18.083. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.006MRQ-29.762+9.756
MRQ-29.762TTM-18.083-11.679
TTM-18.083YOY-5.544-12.538
TTM-18.0835Y-20.624+2.541
5Y-20.62410Y-20.6240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-20.006-2.315-17.691
MRQ-29.762-2.560-27.202
TTM-18.083-2.664-15.419
YOY-5.544-4.122-1.422
5Y-20.624-6.258-14.366
10Y-20.624-6.108-14.516
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Immunovant Inc:

  • The EOD is -21.781. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -32.402. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -20.058. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-21.781MRQ-32.402+10.621
MRQ-32.402TTM-20.058-12.344
TTM-20.058YOY-8.024-12.034
TTM-20.0585Y-287.872+267.814
5Y-287.87210Y-287.8720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-21.781-3.067-18.714
MRQ-32.402-3.251-29.151
TTM-20.058-3.545-16.513
YOY-8.024-5.595-2.429
5Y-287.872-8.315-279.557
10Y-287.872-8.708-279.164
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Immunovant is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 9.01 means the investor is paying $9.01 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Immunovant Inc:

  • The EOD is 6.057. Based on the equity, the company is overpriced. -1
  • The MRQ is 9.010. Based on the equity, the company is overpriced. -1
  • The TTM is 11.642. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD6.057MRQ9.010-2.954
MRQ9.010TTM11.642-2.632
TTM11.642YOY2.817+8.825
TTM11.6425Y9.197+2.446
5Y9.19710Y9.1970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.0571.905+4.152
MRQ9.0102.111+6.899
TTM11.6422.095+9.547
YOY2.8172.836-0.019
5Y9.1973.443+5.754
10Y9.1973.794+5.403
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Immunovant Inc.

3.1. Institutions holding Immunovant Inc

Institutions are holding 47.636% of the shares of Immunovant Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31FMR Inc5.42060.025578758221272761.6426
2023-12-31Vanguard Group Inc4.01110.00545827798-405348-6.5031
2023-12-31BlackRock Inc3.11830.004945307163990519.6584
2023-12-31State Street Corporation2.21370.00663216376-252241-7.2721
2023-12-31Perceptive Advisors LLC1.60232.18932328082-1486609-38.9706
2023-12-31T. Rowe Price Associates, Inc.1.1030.00911602562872520119.5164
2023-12-31Armistice Capital, LLC0.98830.8259143600040012338.6265
2023-12-31Alpine Partners VI, LLC0.962418.8375139837214589811.6488
2023-12-31Adage Capital Partners Gp LLC0.91660.11621331780897280206.5086
2023-12-31Pictet Asset Manangement SA0.89990.0608130743117222615.1714
2023-12-31Geode Capital Management, LLC0.87610.0056127296612863211.2408
2023-12-31Nuveen Asset Management, LLC0.84470.0166122726619905019.3588
2023-12-31Logos Global Management LP0.82594.71911200000-400000-25
2023-12-31Cormorant Asset Management, LLC0.80182.34411165000-60000-4.898
2023-09-30Redmile Group, LLC0.75882.01381102514-818638-42.6118
2023-12-31Deep Track Capital, LP0.68831.4071000000-1797955-64.2596
2023-12-31COMMODORE CAPITAL LP0.68833.6812100000000
2023-12-31Boxer Capital LLC0.68832.0998100000025000033.3333
2023-12-31Rock Springs Capital Management LP0.67681.019898330133895752.605
2023-12-31Capital Research Global Investors0.67190.010197623722623730.1649
Total 28.757139.398341782223-1063541-2.5%

3.2. Funds holding Immunovant Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Growth Compy Commingled Pl O2.20120.1442319824600
2024-03-28SPDR® S&P Biotech ETF1.65941.03162410929304001.277
2024-02-29Fidelity Growth Company Fund1.63690.141237832200
2024-02-29Vanguard Total Stock Mkt Idx Inv1.27620.00421854256-5981-0.3215
2024-02-29Vanguard Small Cap Index1.02670.03751491735138640.9381
2024-03-28iShares Russell 2000 ETF0.90620.06513166486360.0483
2024-02-29Vanguard Small Cap Value Index Inv0.69880.0675101529942240.4178
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.57210.028883121933100.3998
2024-02-29Fidelity Select Biotechnology0.56610.591882254300
2024-02-29Fidelity Growth Company K60.55920.156381243800
2023-12-31American Funds SMALLCAP World A0.53710.045778036718986732.1536
2023-12-31Pictet-Biotech P USD0.4651.80216756726470.0958
2023-12-31US Small-Cap Growth II Equity Comp0.43310.1068629335453014256.9257
2023-12-31T. Rowe Price New Horizons0.43310.1072629335453014256.9257
2024-02-29SEB Läkemedelsfond0.41491.483560285100
2024-02-29Fidelity Series Growth Company0.39880.129857950000
2024-01-31Alger Small Cap Focus I0.39881.3189579438-20000-3.3365
2024-01-31Alger Small Cap Focus Composite0.39881.3189579438-20000-3.3365
2024-01-31Fidelity Small Cap Index0.3760.080254626892981.7316
2024-02-29Franklin Biotechnology Discv A(acc)USD0.35610.99155173708900020.7764
Total 15.31459.652522251209+1201293+5.4%

3.3. Insider Transactions

Insiders are holding 55.501% of the shares of Immunovant Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-09Julia G ButchkoSELL105331.18
2024-04-09Eva Renee BarnettSELL368931.18
2024-04-09Peter SalzmannSELL480731.18
2024-02-22Eva Renee BarnettSELL293036.15
2024-02-22Mark S LevineSELL213436.15
2024-01-26Mark S LevineSELL302737.92
2024-01-18William L MaciasSELL42441.03
2024-01-11Eva Renee BarnettSELL351541.83
2024-01-05Julia G ButchkoSELL129738.59
2024-01-05Peter SalzmannSELL382438.59
2023-11-22Eva Renee BarnettSELL405532.78
2023-11-22Julia G ButchkoSELL326532.78
2023-11-22Peter SalzmannSELL1621732.78
2023-10-25Mark S LevineSELL410734.66
2023-10-19William L MaciasSELL53036.8
2023-10-10Eva Renee BarnettSELL455736.92
2023-10-05Julia G ButchkoSELL173536.24
2023-10-05Peter SalzmannSELL523936.24
2023-10-02Sciences Ltd. RoivantBUY152631638
2023-08-30Peter SalzmannSELL5677422.02

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Immunovant Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.9430.455+546%-0.156+105%0.234+1159%0.234+1159%
Book Value Per Share--4.6762.742+71%2.954+58%2.293+104%2.293+104%
Current Ratio--22.14111.382+95%14.355+54%14.912+48%14.912+48%
Debt To Asset Ratio--0.0450.109-59%0.076-41%0.119-62%0.119-62%
Debt To Equity Ratio--0.0470.124-62%0.083-43%0.704-93%0.704-93%
Dividend Per Share----0%-0%-0%-0%
Eps---0.354-0.419+18%-0.342-3%-0.250-29%-0.250-29%
Free Cash Flow Per Share---0.325-0.362+11%-0.285-12%-0.192-41%-0.192-41%
Free Cash Flow To Equity Per Share--2.9090.448+549%-0.042+101%0.270+976%0.270+976%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---18.760--------
Intrinsic Value_10Y_min---15.965--------
Intrinsic Value_1Y_max---1.200--------
Intrinsic Value_1Y_min---1.178--------
Intrinsic Value_3Y_max---4.124--------
Intrinsic Value_3Y_min---3.926--------
Intrinsic Value_5Y_max---7.672--------
Intrinsic Value_5Y_min---7.077--------
Market Cap4114697533.440-49%6121193752.9604177173520.000+47%1189223139.520+415%2532057294.832+142%2532057294.832+142%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio6.057-49%9.01011.642-23%2.817+220%9.197-2%9.197-2%
Pe Ratio-20.006+33%-29.762-18.083-39%-5.544-81%-20.624-31%-20.624-31%
Price Per Share28.320-49%42.13028.750+47%8.185+415%17.427+142%17.427+142%
Price To Free Cash Flow Ratio-21.781+33%-32.402-20.058-38%-8.024-75%-287.872+788%-287.872+788%
Price To Total Gains Ratio9.624-49%14.317-47.237+430%19.169-25%500.802-97%500.802-97%
Quick Ratio--21.55510.863+98%13.875+55%97.051-78%97.051-78%
Return On Assets---0.072-0.158+118%-0.108+49%-0.092+27%-0.092+27%
Return On Equity---0.076-0.180+138%-0.117+54%-0.103+36%-0.103+36%
Total Gains Per Share--2.9430.455+546%-0.156+105%0.234+1159%0.234+1159%
Usd Book Value--679344000.000398378500.000+71%429186000.000+58%333091353.200+104%333091353.200+104%
Usd Book Value Change Per Share--2.9430.455+546%-0.156+105%0.234+1159%0.234+1159%
Usd Book Value Per Share--4.6762.742+71%2.954+58%2.293+104%2.293+104%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.354-0.419+18%-0.342-3%-0.250-29%-0.250-29%
Usd Free Cash Flow---47229000.000-52639250.000+11%-41411250.000-12%-27842211.750-41%-27842211.750-41%
Usd Free Cash Flow Per Share---0.325-0.362+11%-0.285-12%-0.192-41%-0.192-41%
Usd Free Cash Flow To Equity Per Share--2.9090.448+549%-0.042+101%0.270+976%0.270+976%
Usd Market Cap4114697533.440-49%6121193752.9604177173520.000+47%1189223139.520+415%2532057294.832+142%2532057294.832+142%
Usd Price Per Share28.320-49%42.13028.750+47%8.185+415%17.427+142%17.427+142%
Usd Profit---51418000.000-60862000.000+18%-49674750.000-3%-34533830.550-33%-34533830.550-33%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--2.9430.455+546%-0.156+105%0.234+1159%0.234+1159%
 EOD+2 -6MRQTTM+28 -1YOY+20 -95Y+19 -1010Y+19 -10

4.2. Fundamental Score

Let's check the fundamental score of Immunovant Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-20.006
Price to Book Ratio (EOD)Between0-16.057
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than121.555
Current Ratio (MRQ)Greater than122.141
Debt to Asset Ratio (MRQ)Less than10.045
Debt to Equity Ratio (MRQ)Less than10.047
Return on Equity (MRQ)Greater than0.15-0.076
Return on Assets (MRQ)Greater than0.05-0.072
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Immunovant Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.865
Ma 20Greater thanMa 5030.946
Ma 50Greater thanMa 10033.168
Ma 100Greater thanMa 20036.557
OpenGreater thanClose28.210
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  1,383-531852-270582-69513-1,113-600



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets711,446
Total Liabilities32,102
Total Stockholder Equity679,344
 As reported
Total Liabilities 32,102
Total Stockholder Equity+ 679,344
Total Assets = 711,446

Assets

Total Assets711,446
Total Current Assets710,776
Long-term Assets670
Total Current Assets
Cash And Cash Equivalents 690,937
Net Receivables 1,029
Inventory 0
Other Current Assets 18,810
Total Current Assets  (as reported)710,776
Total Current Assets  (calculated)710,776
+/-0
Long-term Assets
Property Plant Equipment 670
Long-term Assets  (as reported)670
Long-term Assets  (calculated)670
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities32,102
Long-term Liabilities0
Total Stockholder Equity679,344
Total Current Liabilities
Short-term Debt 306
Accounts payable 3,910
Other Current Liabilities 27,886
Total Current Liabilities  (as reported)32,102
Total Current Liabilities  (calculated)32,102
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock14
Retained Earnings -750,364
Accumulated Other Comprehensive Income -600
Other Stockholders Equity 1,430,294
Total Stockholder Equity (as reported)679,344
Total Stockholder Equity (calculated)679,344
+/-0
Other
Capital Stock14
Cash and Short Term Investments 690,937
Common Stock Shares Outstanding 144,523
Liabilities and Stockholders Equity 711,446
Net Debt -690,631
Net Invested Capital 679,344
Net Working Capital 678,674
Property Plant and Equipment Gross 670
Short Long Term Debt Total 306



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-06-30
> Total Assets 
0
325
117,416
117,787
126,619
109,387
290,291
453,895
433,029
412,489
388,027
566,732
543,182
515,564
458,656
428,146
456,243
405,838
351,222
292,070
711,446
711,446292,070351,222405,838456,243428,146458,656515,564543,182566,732388,027412,489433,029453,895290,291109,387126,619117,787117,4163250
   > Total Current Assets 
0
148
2,074
1,762
126,570
109,076
286,116
450,266
429,428
409,006
384,826
563,792
540,480
512,931
456,304
426,091
454,422
404,333
350,015
291,177
710,776
710,776291,177350,015404,333454,422426,091456,304512,931540,480563,792384,826409,006429,428450,266286,116109,076126,5701,7622,0741480
       Cash And Cash Equivalents 
0
148
1,912
1,610
123,530
100,571
280,279
444,372
421,974
400,146
379,005
558,952
527,003
493,817
427,205
405,773
432,608
376,532
329,960
269,928
690,937
690,937269,928329,960376,532432,608405,773427,205493,817527,003558,952379,005400,146421,974444,372280,279100,571123,5301,6101,9121480
       Short-term Investments 
0
0
115,342
116,025
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000116,025115,34200
       Net Receivables 
0
0
2,996
2,926
2,996
3,045
24
40
481
548
548
0
0
12,861
13,177
3,782
704
885
823
1,421
1,029
1,0291,4218238857043,78213,17712,8610054854848140243,0452,9962,9262,99600
       Other Current Assets 
0
177
162
152
44
5,460
5,813
5,854
6,973
8,312
5,821
4,840
13,477
6,253
15,922
16,536
21,110
26,916
19,232
19,828
18,810
18,81019,82819,23226,91621,11016,53615,9226,25313,4774,8405,8218,3126,9735,8545,8135,460441521621770
   > Long-term Assets 
0
177
115,342
116,025
49
311
4,175
3,629
3,601
3,483
3,201
2,940
2,702
2,633
2,352
2,055
1,821
1,505
1,207
893
670
6708931,2071,5051,8212,0552,3522,6332,7022,9403,2013,4833,6013,6294,17531149116,025115,3421770
       Property Plant Equipment 
0
0
42
45
49
65
4,175
3,629
3,601
3,483
3,201
2,940
2,702
2,633
2,352
2,055
1,821
1,505
1,207
893
670
6708931,2071,5051,8212,0552,3522,6332,7022,9403,2013,4833,6013,6294,1756549454200
       Other Assets 
0
0
1,398
1,678
0
246
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000024601,6781,39800
> Total Liabilities 
0
300
4,116
4,363
14,757
15,318
22,516
15,489
18,877
21,009
22,495
30,335
38,034
45,739
22,163
32,398
41,565
43,344
51,357
40,259
32,102
32,10240,25951,35743,34441,56532,39822,16345,73938,03430,33522,49521,00918,87715,48922,51615,31814,7574,3634,1163000
   > Total Current Liabilities 
0
300
91
338
14,757
15,318
19,544
12,810
16,485
18,771
20,523
28,383
36,354
44,520
21,244
31,784
41,259
43,297
51,357
40,259
32,102
32,10240,25951,35743,29741,25931,78421,24444,52036,35428,38320,52318,77116,48512,81019,54415,31814,757338913000
       Short-term Debt 
0
300
300
0
0
0
1,102
1,102
1,104
1,179
1,085
1,082
1,079
1,145
1,165
1,185
1,205
1,173
919
614
306
3066149191,1731,2051,1851,1651,1451,0791,0821,0851,1791,1041,1021,1020003003000
       Short Long Term Debt 
0
300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000003000
       Accounts payable 
0
0
516
1,176
2,812
1,190
8,011
5,787
2,100
2,432
3,107
4,243
3,827
18,629
1,066
7,461
14,004
1,353
26,459
7,511
3,910
3,9107,51126,4591,35314,0047,4611,06618,6293,8274,2433,1072,4322,1005,7878,0111,1902,8121,17651600
       Other Current Liabilities 
0
0
91
338
11,945
14,128
10,431
5,921
13,281
15,160
16,331
23,058
31,448
24,746
19,013
23,138
26,050
40,771
23,979
32,134
27,886
27,88632,13423,97940,77126,05023,13819,01324,74631,44823,05816,33115,16013,2815,92110,43114,12811,9453389100
   > Long-term Liabilities 
0
300
4,025
4,025
2,812
1,190
2,972
2,679
2,392
2,238
1,972
1,952
1,680
1,219
919
614
306
47
0
0
0
000473066149191,2191,6801,9521,9722,2382,3922,6792,9721,1902,8124,0254,0253000
       Deferred Long Term Liability 
0
0
1,398
1,678
0
246
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000024601,6781,39800
> Total Stockholder Equity
-1,497
24
113,299
113,425
111,862
94,069
267,775
438,406
414,152
391,480
365,532
536,397
505,148
469,825
436,493
395,748
414,678
362,494
299,865
251,811
679,344
679,344251,811299,865362,494414,678395,748436,493469,825505,148536,397365,532391,480414,152438,406267,77594,069111,862113,425113,29924-1,497
   Common Stock
0
0
108,300
108,425
5
5
8
10
10
10
10
12
12
12
12
12
13
13
13
13
14
1413131313121212121210101010855108,425108,30000
   Retained Earnings Total Equity00-640,284-566,347-506,915-443,688-395,760-355,387-308,216-266,831-198,657-198,657-170,49900000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-147
-16
10
-222
467
-298
273
442
419
404
-263
-1,237
1,383
852
582
513
-600
-6005135828521,383-1,237-263404419442273-298467-22210-16-1470000
   Capital Surplus 
0
25
4,818
4,693
182,679
185,306
0
0
584,174
590,425
590,425
802,774
812,933
824,796
832,504
840,661
920,197
927,976
939,554
0
0
00939,554927,976920,197840,661832,504824,796812,933802,774590,425590,425584,17400185,306182,6794,6934,818250
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
25
4,818
4,693
182,679
185,306
385,691
577,341
584,174
590,425
594,377
802,774
812,933
824,796
832,504
840,661
920,197
927,976
939,554
950,231
1,430,294
1,430,294950,231939,554927,976920,197840,661832,504824,796812,933802,774594,377590,425584,174577,341385,691185,306182,6794,6934,818250



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,324
Gross Profit-1,324-1,324
 
Operating Income (+$)
Gross Profit-1,324
Operating Expense-208,276
Operating Income-198,469-209,600
 
Operating Expense (+$)
Research Development160,257
Selling General Administrative48,019
Selling And Marketing Expenses0
Operating Expense208,276208,276
 
Net Interest Income (+$)
Interest Income7,578
Interest Expense-12,482
Other Finance Cost-12,482
Net Interest Income7,578
 
Pretax Income (+$)
Operating Income-198,469
Net Interest Income7,578
Other Non-Operating Income Expenses-253
Income Before Tax (EBT)-210,951-185,987
EBIT - interestExpense = -210,951
-210,951
-198,478
Interest Expense12,482
Earnings Before Interest and Taxes (EBIT)-198,469-198,469
Earnings Before Interest and Taxes (EBITDA)-198,276
 
After tax Income (+$)
Income Before Tax-210,951
Tax Provision-9
Net Income From Continuing Ops-210,960-210,960
Net Income-210,960
Net Income Applicable To Common Shares-210,960
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring10,000
Other Operating Expenses208,276
Total Other Income/Expenses Net-12,482-7,325
 

Technical Analysis of Immunovant
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Immunovant. The general trend of Immunovant is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Immunovant's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Immunovant Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 33.95 < 35.97 < 39.55.

The bearish price targets are: 25.13 > 24.27 > 19.50.

Tweet this
Immunovant Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Immunovant Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Immunovant Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Immunovant Inc. The current macd is -1.09379672.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Immunovant price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Immunovant. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Immunovant price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Immunovant Inc Daily Moving Average Convergence/Divergence (MACD) ChartImmunovant Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Immunovant Inc. The current adx is 15.62.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Immunovant shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Immunovant Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Immunovant Inc. The current sar is 32.58.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Immunovant Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Immunovant Inc. The current rsi is 33.87. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Immunovant Inc Daily Relative Strength Index (RSI) ChartImmunovant Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Immunovant Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Immunovant price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Immunovant Inc Daily Stochastic Oscillator ChartImmunovant Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Immunovant Inc. The current cci is -188.96008897.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Immunovant Inc Daily Commodity Channel Index (CCI) ChartImmunovant Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Immunovant Inc. The current cmo is -38.28568906.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Immunovant Inc Daily Chande Momentum Oscillator (CMO) ChartImmunovant Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Immunovant Inc. The current willr is -92.5170068.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Immunovant Inc Daily Williams %R ChartImmunovant Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Immunovant Inc.

Immunovant Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Immunovant Inc. The current atr is 1.53545415.

Immunovant Inc Daily Average True Range (ATR) ChartImmunovant Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Immunovant Inc. The current obv is 68,408,714.

Immunovant Inc Daily On-Balance Volume (OBV) ChartImmunovant Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Immunovant Inc. The current mfi is 34.19.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Immunovant Inc Daily Money Flow Index (MFI) ChartImmunovant Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Immunovant Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Immunovant Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Immunovant Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.865
Ma 20Greater thanMa 5030.946
Ma 50Greater thanMa 10033.168
Ma 100Greater thanMa 20036.557
OpenGreater thanClose28.210
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Immunovant with someone you think should read this too:
  • Are you bullish or bearish on Immunovant? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Immunovant? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Immunovant Inc

I send you an email if I find something interesting about Immunovant Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Immunovant Inc.

Receive notifications about Immunovant Inc in your mailbox!